首页> 外文期刊>The Thoracic and cardiovascular surgeon >Surgical Treatment for Lung Cancer with COPD Based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
【24h】

Surgical Treatment for Lung Cancer with COPD Based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

机译:基于全球慢性阻塞性肺疾病倡议(GOLD)的COPD肺癌手术治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: The surgical indications for non-small cell carcinoma (NSCLC) with chronic obstructive pulmonary disease (COPD) are not well known. A classification of severity in COPD has been newly recommended by the US National Heart, Lung, and Blood Institute (NHLBI) and the World Health Organization (WHO). Therefore, based on this new system of classification, we review here a series of NSCLC patients with COPD who underwent lung resection at our hospital and attempt to identify the survival and morbidity of such patients. METHODS: We retrospectively reviewed the patients with NSCLC treated at our hospital between January 1994 and December 2002. Among these 640 patients, a curative approach was attempted in 50 with COPD (31 lobectomies, 11 segmentectomies, 8 bilobectomies). The patients were consequently divided into two groups (moderate group and severe group) according to the Global Iinitiative for Chronic Obstructive Lung disease (GOLD). Lung function was evaluated by FEV1 and FVC, and the survival rates were analyzed at 5 years. Postoperative morbidity was also compared between the two groups. RESULTS: FEV1 was 1.527 +/- 0.311 L in the moderate group compared with 1.025 +/- 0.224 L in the severe group ( p < 0.001). Postoperative decrease in FEV1 was lower compared to the predicted data of patients who underwent surgery for NSCLC with COPD. Postoperative pulmonary support such as mechanical ventilation or tracheotomy were necessary more frequently in the severe group. A significant difference was observed between the two groups in respiratory support ( p = 0.0102). Overall 5-year survival rate for NSCLC with COPD was 73.9 %, although there was no statistically significant difference between the moderate and severe groups in terms of survival. Lobectomy and segmentectomy show a remarkable advantage for the patients with bilobectomy, although this difference was not statistically significant. On the other hand, gender, degree of COPD, and histological type were shown to be not significant factors. Survival rate of these NSCLC patients with COPD were demonstrated to be comparable to those of the NSCLC patients without COPD in stages I and II. CONCLUSION: Stringent selection of candidates among NSCLC patients with a severe grade of COPD based on GOLD could be an acceptable and valuable approach compared to conventional patients without COPD, although NSCLC with severe COPD patients more frequently needed respiratory support.
机译:目的:慢性阻塞性肺疾病(COPD)的非小细胞癌(NSCLC)的手术适应症尚不清楚。美国国家心脏,肺和血液研究所(NHLBI)和世界卫生组织(WHO)新近推荐了COPD的严重程度分类。因此,基于这种新的分类系统,我们在这里回顾了在我们医院接受了肺切除术的一系列患有COPD的NSCLC患者,并试图确定这些患者的存活率和发病率。方法:我们回顾性回顾了1994年1月至2002年12月在我院接受治疗的NSCLC患者。在这640例患者中,尝试对50例COPD患者(31例肺叶切除,11例肺叶切除,8例双肺切除)进行了治愈。因此,根据全球慢性阻塞性肺疾病的起因(GOLD)将患者分为两组(中度组和重度组)。通过FEV1和FVC评估肺功能,并分析5年生存率。还比较了两组的术后发病率。结果:中度组FEV1为1.527 +/- 0.311 L,而重度组为1.025 +/- 0.224 L(p <0.001)。与接受COPD的NSCLC手术患者的预测数据相比,FEV1的术后降低幅度更低。重症组更需要术后肺支持,例如机械通气或气管切开术。两组在呼吸支持方面存在显着差异(p = 0.0102)。 NSCLC合并COPD的5年总生存率为73.9%,尽管中,重度组在生存率上无统计学差异。肺叶切除术和节段切除术对双叶切除术患者显示出显着优势,尽管这种差异在统计学上并不显着。另一方面,性别,COPD程度和组织学类型不是重要因素。这些患有COPD的非小细胞肺癌患者的生存率在I和II期与未患有COPD的非小细胞肺癌患者的生存率相当。结论:与传统的无COPD的患者相比,严格选择具有GOLD的重度COPD的NSCLC患者可能是一种可接受且有价值的方法,尽管重度COPD患者的NSCLC更需要呼吸支持。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号